Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
 
 
 
Blog Home
Bob Carey
Chief Market Strategist
Click for Bio

Follow Bob on Twitter Follow Bob on LinkedIn View Videos on YouTube
 

  Biotech Pipelines and “Pharmerging Markets” offer Growth Potential
Posted Under: Sectors
Supporting Image for Blog Post

 

View from the Observation Deck

  1. Global pharmaceutical sales by PhRMA member companies totaled an estimated $295.5 billion in 2011 (see chart), with 38% occurring outside the U.S. In 2006, that figure was 30%.
  2. These nations followed the U.S.'s 62% share of global sales (by PhRMA members): Japan (4.6%); France (3.3%); Germany (2.7%); Italy (2.3%); and Canada (2.3%).
  3. So-called "Big Pharma" is looking to expand heavily into emerging markets ("pharmerging"), particularly in Brazil, Russia, India & China (BRICs), where governments are investing more in health care. (IMAP, Inc.)
  4. In 2010, the BRIC countries accounted for about 3.5% of total global sales. (PhRMA)
  5. Approximately $89.5 billion worth of branded pharmaceuticals are scheduled to lose patent protection between 2009 and 2014. Generic sales are expected to grow from $107.8 billion in 2009 to $129.3 billion in 2014. (IMAP, Inc.)
  6. Biologic sales, on the other hand, are expected to grow by $41 billion between 2009 and 2014. (IMAP, Inc.)
  7. The fastest way for a drug company to acquire new medicines is through mergers and acquisitions and through licensing agreements, in our opinion.
  8. In 2012, some drug companies have been willing to pay premiums 71%, on average, above a biotechnology company's average 20-day stock price (deals > $500 million in 2012) to acquire them. (Bloomberg)
Posted on Tuesday, May 1, 2012 @ 4:32 PM • Post Link Share: 
Print this post Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Search Posts
MARKET ANALYSIS


 PREVIOUS POSTS
The Markets Fight Through the Headlines
US Economy and Credit Markets Week Ended April 27, 2012
US Stocks Week Ended April 27, 2012
China May Only Pose a Near-Term Challenge for Price of Copper
Agriculture Prices Take Breather Following Strong Decade
US Economy and Credit Markets Week Ended April 20, 2012
US Stocks Week Ended April 20, 2012
It’s Tough To Stay On Top!
Job Creation to Drive REIT Recovery from this Point Forward
The Question of Recession
Archive
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

 
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2022 All rights reserved.